三生国健重组抗IL-4Rα人源化单克隆抗体注射液新药上市申请获得受理

Core Viewpoint - Sanofi Guojian has received the acceptance notice from the National Medical Products Administration for its new drug application of SSGJ-611, a humanized monoclonal antibody targeting IL-4Rα, which is expected to alleviate atopic dermatitis and other diseases [1] Group 1 - The product SSGJ-611 is a self-developed and designed humanized monoclonal antibody with a novel amino acid sequence [1] - SSGJ-611 works by specifically binding to IL-4Rα, blocking the signaling pathways of IL-4 and IL-13 [1] - The acceptance of the new drug application marks a significant step for the company in the biopharmaceutical industry [1]